# Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

> **NCT00750815** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 58 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)

## Key facts

- **NCT ID:** NCT00750815
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-12
- **Final completion:** 2013-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2014-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750815, "Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00750815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*